
PepGen Inc (PEPG) Stock Forecast & Price Target
PepGen Inc (PEPG) Analyst Ratings
Bulls say
PepGen Inc., a clinical-stage biotechnology company, is poised for significant growth, with shares currently trading around $4, indicating potential upside should upcoming multi-dose data demonstrate a favorable risk/benefit profile. The company's Enhanced Delivery Oligonucleotide platform has shown impressive preclinical results, with a reported splicing correction of 53.7% for its product PGN-EDO51, surpassing competitors and suggesting a potential for meaningful enhancements in muscle performance. Additionally, the successful demonstration of efficacy in its pipeline, particularly in neuromuscular and neurologic disease treatments, positions PepGen advantageously within the biotech sector, reflecting a strong potential for future value appreciation.
Bears say
PepGen Inc. has reduced its target price to $8 per share amid concerns about its ability to execute commercially and meet or exceed expectations, which could negatively impact its stock performance. Despite the promising data regarding its DM1 therapy and its Enhanced Delivery Oligonucleotide platform, PepGen faces significant competitive pressures that may hinder its market positioning. Moreover, the company may experience delays or the termination of development campaigns if it fails to access the capital markets effectively, further contributing to a negative outlook on its financial prospects.
This aggregate rating is based on analysts' research of PepGen Inc and is not a guaranteed prediction by Public.com or investment advice.
PepGen Inc (PEPG) Analyst Forecast & Price Prediction
Start investing in PepGen Inc (PEPG)
Order type
Buy in
Order amount
Est. shares
0 shares